Monoclonal antibody anti-human progastrin for use in the treatment of pancreatic cancer in which the antibody comprises - a variable heavy chain region wherein CDR1 comprises the amino acid sequence of SEQ ID NO: 1, CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and CDR3 comprising the amino acid sequence of SEQ ID NO: 3 and a variable light chain region wherein CDR1 comprises the amino acid sequence of SEQ ID NO: 4, CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and CDR3 comprising the amino acid sequence of SEQ ID NO: 6 or - a variable heavy chain region wherein CDR1 comprises the amino acid sequence of SEQ ID NO: 37, CDR2 comprising the amino acid sequence of SEQ ID NO: 41, and CDR3 comprising the amino acid sequence of No. SEQ ID: 45 and a variable light chain region wherein CDR1 comprises the amino acid sequence of SEQ ID NO: 49, CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and CDR3 it comprises the amino acid sequence of SEQ ID NO: 55 or - a variable heavy chain region wherein CDR1 comprises the amino acid sequence of SEQ ID NO: 38, CDR2 comprising the amino acid sequence of SEQ ID NO: 42, and CDR3 comprising the amino acid sequence of No. SEQ ID: 46 and a variable light chain region wherein CDR1 comprises the amino acid sequence of SEQ ID NO: 50, CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and CDR3 it comprises the amino acid sequence of SEQ ID NO: 56 or - a variable heavy chain region wherein CDR1 comprises the amino acid sequence of SEQ ID NO: 39, CDR2 comprising the amino acid sequence of SEQ ID NO: 43, and CDR3 comprising the amino acid sequence of No. SEQ ID: 47 and a variable light chain region wherein CDR1 comprises the amino acid sequence of SEQ ID NO: 50, CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and CDR3 it comprises the amino acid sequence of SEQ ID NO: 57 - a variable heavy chain region wherein CDR1 comprises the amino acid sequence of SEQ ID NO: 40, CDR2 comprising the amino acid sequ
